ABLIM1

Across TCGA pan-cancer cohorts, ABLIM1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ABLIM1 data layer compared with 20 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ABLIM1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ABLIM1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

BRCA, UCEC, and DLBC are the cancer types where ABLIM1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.573	0.963	<.001	24	view →
UCEC	DFS	Median	All	0.970	0.621	.006	14	view →
DLBC	DFS	Median	II,III,IV	0.022	0.837	<.001	12	view →
PAAD	OS	Median	All	0.087	0.640	<.001	12	view →
PRAD	DFS	Median	All	0.086	0.776	<.001	6	view →
BLCA	OS	Median	II,III,IV	1.000	0.701	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ABLIM1–BRCA (OS)

Open the BRCA breakdown →